Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05489289
PHASE3

A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection

Sponsor: Akeso

View on ClinicalTrials.gov

Summary

The efficacy and safety of AK104 as adjuvant therapy in hepatocellular carcinoma of high recurrence risk after curative resection.

Official title: A Randomized, Double-blind, Phase III Clinical Study on the Efficacy and Safety of AK104 Versus Placebo as Adjuvant Therapy for Hepatocellular Carcinoma With High Risk of Recurrence After Curative Resection

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

570

Start Date

2023-01-05

Completion Date

2027-01-01

Last Updated

2025-03-12

Healthy Volunteers

No

Interventions

BIOLOGICAL

AK104

Subjects will receive AK104 until disease progression or for a maximum of 16 cycles

BIOLOGICAL

placebo

Subjects will receive placebo until disease progression or for a maximum of 16 cycles

Locations (1)

Zhongshan Hospital, Fudan University

Shanghai, Shanghai Municipality, China